New, Updated Data Demonstrate Promising Future in Advanced Melanoma
Source: OncLive, January 2022
Jeffrey S. Weber, MD, PhD, overviews the successes made in the melanoma setting in the past decade and the challenges to overcome in the future.
Long-term and recent data readouts have fueled immunotherapeutic advances in the treatment of advanced melanoma. At the 6th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application, Jeffrey S. Weber, MD, PhD, presented findings from efficacious trials that have expanded the treatment options for patients with melanoma.
Notably, outcomes of the KEYNOTE 716 trial (NCT03553836) showed that at a median follow-up of 14.4 months pembrolizumab (Keytruda; n = 487) significantly prolonged recurrence-free survival (RFS) vs placebo (n = 489; HR, 0.65; 95% CI, 0.46-0.92; P = .00658) in patients with stage IIB (n = 624) and stage IIC (n = 339) melanoma. Specifically, 54 patients (11.1%) vs 82 patients (16.8%) had a recurrence event and 23 (4.7%) vs 38 (7.7%) had distant recurrence events in the pembrolizumab and placebo groups, respectively. The 12-month RFS rates were 90.5% vs 83.1%, respectively.